Afa Guhua Chun Ruanjiaonang (阿法骨化醇软胶囊)阿法骨化醇软胶囊
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 南通华山药业有限公司Chinese legal name: 南通华山药业有限公司
主要成分Active Ingredients
- 阿法骨化醇Afa Guhua Chun
- 开环胆甾Kaihuan Danzai
药物知识说明
阿法骨化醇是一种在国家药监局注册认定的药品。该药品含有开环胆甾、阿法骨化醇-38eb6e7a等成分。
该药品关联的活性成分包括：开环胆甾Kaihuan Danzai、阿法骨化醇Afa Guhua Chun。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：南通华山药业有限公司Chinese legal name: 南通华山药业有限公司。
您可以探索含有相同成分的其他药品：开环胆甾-dde62f71成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 阿法骨化醇软胶囊) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 开环胆甾Kaihuan Danzai, 阿法骨化醇Afa Guhua Chun.
Manufacturers recorded for this product: 南通华山药业有限公司Chinese legal name: 南通华山药业有限公司.
Explore other medicines containing the same ingredient: 开环胆甾 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 阿法骨化醇软胶囊Recorded Chinese name: 阿法骨化醇软胶囊
- 剂型Dosage form: 胶囊剂Capsules
- 规格Specification: 0.25μg*20粒0.25 μg × 20 capsules
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 南通华山药业有限公司Chinese legal name: 南通华山药业有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20000065
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20000065
Manufacturer
Chinese legal name: 南通华山药业有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
0.25 μg × 20 capsules
中文说明书原文Original Chinese source label
批准文号
国药准字H20000065
生产企业
南通华山药业有限公司(国产)
适应症
1.骨质疏松症。 2.维生素D缺乏性佝偻病和软骨病，跖骨头骨软骨病。 3.肾性骨病。 4.甲状旁腺功能减退症。
用法用量
口服: 1.成人，骨质疏松症和慢性肾功能不全:每次0.5μg(2粒)，每日1次，或遵医嘱。 2.儿童，应遵医嘱。
不良反应
1.小剂量单独使用(<1.0μg/d)一般无不良反应，长期大剂量用药或与钙剂合用可能会引起高钙血症和高钙尿症。
2.偶见食欲不振、恶心、呕吐及皮肤瘙痒感等。
禁忌
对维生素D及其类似物过敏、具有高钙血症、有维生素D中毒征象者禁用。
注意事项
1.青年患者只限用于青年特发性骨质疏松症及糖皮质激素过多引起的骨质疏松症。
2.用药过程中应注意监测血钙、血尿素氮、肌酐，以及尿钙、尿肌酐。
3.出现高钙血症时须停药，并予有关处理，待血钙恢复正常，按末次剂量减半给药。
4.超大剂量服药可能出现胃肠道系统、肝脏方面、精神神经系统、循环系统等方面的不良反应，如：胃痛、便秘、GOT及GPT升高、头痛、血压轻度升高等。
贮藏
密封，在避光处干燥处保存。
规格
0.25μg*20粒
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.